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Graft surveillance: Venous pressure, access flow, or the combi- Thrombosis remains a major problem in vascular ac-
nation? cess for hemodialysis, particularly in polytetrafluoro-
Background. Increased venous pressure (VP) and decreased ethylene (PTFE) grafts. It accounts for considerableaccess flow (Qa) are predictors of dialysis access graft thrombo-
morbidity and mortality, with an annual cost of close tosis. VP is easily obtainable. Qa assessment requires a special
$1 billion in the United States, and is responsible for 17device and takes more time. The aims of our randomized
multicenter studies were to compare outcome in patients with to 25% of all hospitalizations in dialysis patients [1–3].
grafts monitored by VP or Qa (study A) or monitored by VP Thrombosis occurs at a rate of 0.5 to 2.5 events per
or the combination of VP and Qa (study B). patient-year [4–8]. In most cases, thrombosis is associatedMethods. We performed VP measurements consisting of
with the presence of stenoses at the venous anastomosisweekly VP at a pump flow of 200 mL/min (VP200) and the
or in the outflow tract [9–13]. Stenosis increases resistanceratio of VP0/MAP. Qa was measured every eight weeks with
the Transonic HD01 hemodialysis monitor. Threshold levels over the flow tract. Because the graft has no autoregulat-
for referral for angiography were VP200 .150 mm Hg or ing capacities, blood flow (Qa) drops and venous pressures
VP0/MAP .0.5 (both at 3 consecutive dialysis sessions) or Qa
(VP) rise. These variables have been shown to predict,600 mL/min. Subsequent therapy consisted of either percuta-
thrombosis. More importantly, several studies demon-neous transluminal angioplasty (PTA) or surgery.
Results. Total follow-up was 80.5 patient-years for 125 grafts. strated that referral for corrective intervention based on
The vast majority of a total of 131 positive tests was followed these parameters can prevent thrombosis [14–18].
by angiography and corrective intervention. In study A, the We and others confirmed that patients with outflow
rate of thromboses not preceded by a positive test was 0.19
stenosis have on average a higher VP and/or lower Qaand 0.24 per patient-year (P 5 NS), and in study B, it was 0.32
[14, 19]. However, VP did not correlate with Qa. In otherversus 0.28 per patient-year (P 5 NS). Survival curves were
not significantly different between the subgroups. words, not all patients with high VP had low Qa, indicat-
Conclusions. These data demonstrate that standardized ing that not all patients who are at risk for thrombosis
monitoring of either VP or Qa or the combination of both and can be identified by VP measurements. We also showedsubsequent corrective intervention can reduce thrombosis rate
that inflow resistance (that is, the resistance of the flowin grafts to below the recommended quality of care standard
tract upstream of the venous needle) comprises a sub-(that is, 0.5 per patient-year, NKF-DOQI). These surveillance
strategies are equally effective in reducing thrombosis rates. stantial and very variable part of total graft resistance.
Indeed, several studies have indicated that in up to 29%
of thrombosis cases, stenoses may be located in the arte-
rial part of the graft [13, 20–23]. The inflow resistance
is not reflected by VP measurements, whereas Qa mea-
surements are a reflection of total graft resistance. This
1 Dr. Smits and Dr. van der Linden contributed equally to this study. could make VP less effective as selection parameter for
patients at risk for thrombosis than Qa. In contrast toKey words: vascular access, graft thrombosis, PTFE, hemodialysis,
monitoring for stenosis. Qa measurements, VP can be measured by the dialysis
machine, is easy to obtain, and requires little time invest-Received for publication July 12, 2000
ment. Furthermore, some studies have convincingly indi-and in revised form October 6, 2000
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ography section), measurements were repeated the next
dialysis session. All centers had dialysis machines with
digital pressure displays. Maintenance and calibration
were done according to the manufacturer’s recommen-
dations on a regular basis by an experienced technician.
Dynamic venous pressure. Digitally displayed dy-
Fig. 1. Study design. namic VPs were assessed with a fixed pump flow set at
200 mL/min (VP200), as described by Schwab et al [16].
Ten subsequent readings on the dialyzer display were
averaged. After the measurement, the pump flow wasdures results in thrombosis rates between 0.2 and 0.4
set to the original level.events per patient-year [6, 14, 16]. Although we provided
Static venous pressure. Static VP (VP0) was assessedthe theoretical basis that Qa measurements are better
with zero pump flow with the tubing out of the air lockthan VP measurements, the question is whether Qa mea-
in order to avoid automatic closure of the tubing aftersurements really confer additional benefit in patients
the pump was shut off. VP0 was divided by mean arterialwho are monitored by VP. In other words, when simple
pressure (MAP) to correct for blood pressure differencesclinical variables such as VP are used, is there any addi-
as described by Besarab et al [14]. No correction fortional benefit when periodic Qa measurements are added
height differences was made. MAP was calculated byto the surveillance protocol?
taking two times the diastolic pressure plus systolic pres-Our hypothesis for the present studies was as follows:
sure divided by three.Qa measurements are better than VP measurements in
identifying patients at risk for thrombosis. As a conse-
Access flow measurementquence, referral of patients for corrective interventions
based on Qa measurements alone or on the combination Measurements were done every eight weeks. Qa was
of VP and Qa reduces the thrombosis rate more than measured with the Transonic Hemodialysis Monitor
the referral based on VP alone. (Transonic Systems Inc., Ithaca, NY, USA). The theoret-
ical background, bench validation, and in vivo validation
are described in detail in previous articles [24, 25]. Peri-METHODS
odic calibration was done by the local distributor. Qa
Patients
determination consisted of the average of three consecu-
Five dialysis centers participated in this study. All pa- tive measurements. If Qa levels reached between 600
tients with a hemodialysis access PTFE graft were eligi- and 800 mL/min, the measurement was repeated after
ble to enter into the study. Exclusion criteria were inabil- one month. All measurements were done with a dialyzer
ity to give informed consent and contrast allergy. blood flow of more than 200 mL/min.
Studies were approved by the institutional ethical re-
view committees. Informed consent was obtained from Indication for referral for angiography
all patients.
Referral of group A1 patients for angiography was
based on three consecutive dialysis sessions with ele-Surveillance protocols
vated static and/or dynamic VP. Patients in group A2Two surveillance studies were conducted concur-
underwent angiography when Qa fell below 600 mL/min.rently. In study A, patients were assigned to weekly VP
Indication for referral of group B1 patients for angiogra-measurements (group A1) or periodic Qa measurements
phy was an elevated static and/or dynamic VP, similar(group A2). In study B, patients were assigned to weekly
to group A1. In group B2, an elevated static and/orVP measurements (group B1) or the combination of VP
dynamic VP and/or Qa below 600 mL/min were reasonsmeasurements and periodic Qa measurements (group
for referral. The threshold level for the static VP ratioA2). Study A was instituted in one center (Rotterdam)
was 0.5, according to the method described by Besaraband study B in four centers. Within the centers, the
et al [14]. Threshold for dynamic VP was 150 mm Hg.patients were allocated prospectively and randomly to
Angiography was done to determine the presence andone of the subgroups of each study (Fig. 1).
location of the stenosis. If a stenosis of .50% was pres-
Venous pressure monitoring ent, the primary choice of treatment was percutaneous
transluminal angioplasty (PTA). After an intervention,Measurements were done once weekly within the first
patients continued the same surveillance mode as before.half hour of dialysis and included both dynamic and
All thrombotic events and interventions (elective orstatic VP measurements. When one or both measure-
ments were positive (see Indication for referral for angi- therapeutic) were recorded.
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Data analysis are depicted in Table 1. There were no significant differ-
ences in age, percentage of diabetics, race, or time onThrombosis-free survival rates between the subgroups
hemodialysis therapy, in either studies A or B.in both groups were tested with the log rank test. Curves
were made with Kaplan–Meier survival analysis showing Outcome
event-free graft survival. An event was defined as a
Study A. Total follow-up was 37.8 patient-years. Graftthrombotic event without a preceding positive test, either
monitoring resulted 59 times in positive tests followedVP (groups A1, B1, and B2) or Qa (groups A2 and B2).
by 55 angiograms, which subsequently resulted in 48Differences between incidence rates of thrombosis and
PTA procedures and 7 surgical interventions. Table 2
of intervention were calculated with Poisson regression shows which test(s) led to these interventions. In all cases
analysis. A P value of less than 0.05 was considered of group A1, it was an increased VP0/MAP, which led
significant. to the intervention. In the vast majority of angiograms,
venous stenoses were present (Table 3). Graft character-Power analysis
istics and outcomes of individual patient groups are out-
For calculation of group sizes, we made the following lined in Tables 4 and 5.
assumptions. Our historical thrombosis rate was 1.2 During the follow-up, 12 thrombotic events occurred
event per patient-year [7], but improved after intensi- (6 in each patient group), resulting in a thrombosis fre-
fying access surveillance using dynamic VP measure- quency of 0.31 per patient-year. In both subgroups,
ments to approximately 0.85. At that time, however, no thrombosis was predicted by a positive test (VP or Qa)
specific surveillance protocol was used. We expected the in two occasions, but thrombosis occurred pending the
thrombosis rate in the Qa groups to be lower than in angiography (2 to 15 days after obtaining positive tests).
the VP groups based on considerations described pre- In eight grafts, thrombosis was not preceded by an abnor-
viously in this article. We calculated that with a follow- mal VP or flow, which resulted in an unpredicted throm-
bosis rate of 0.19 and 0.24 per patient-year (P 5 NS).up of 100 patient-years, a thrombosis rate difference
No anatomical information is available from these eightof 0.25 could be demonstrated (a 5 0.05, b 5 0.20).
grafts with thrombosis. Reasons included no attempt toObviously, for differences of greater than 0.25, less fol-
reestablish patency or surgical thrombectomy withoutlow-up is needed.
intraoperative angiography.
Kaplan–Meier survival curves did not show a signifi-
RESULTS cant difference between the subgroups (Table 5 and
Fig. 2). The six-month event-free survival (an eventData were evaluated after a follow-up of approxi-
equals thrombosis not predicted by the test) was 87%mately two times 40 patient-years. An interim analysis
for the VP group and 84% for the Qa group (P 5 NS).showed that results in VP monitored grafts were much
Study B. The total follow-up period was 42.7 patient-better than anticipated. This justified the conclusion that
years. Graft monitoring resulted 72 times in positive teststhe continuation of the study was not likely to result in
followed by 55 angiograms, which subsequently resultedclinically significant differences.
in 49 PTA procedures and 6 surgical interventions.
Table 2 shows which positive test(s) led to an interven-Patient characteristics
tion. In 90% of cases, there was an elevated VP0/MAP.Study A included 53 PTFE grafts (51 patients). Twenty-
Venous stenosis (at or near the venous anastomosis orfive grafts were monitored by VP (group A1) and 28
in the venous outflow tract) was present in 98% of thegrafts by Qa measurements (group A2). Study B in-
grafts treated with PTA (Table 3). Graft characteristics
cluded 72 grafts (68 patients). Thirty-one grafts were
and outcomes of individual patient groups are outlined
assigned to group B1 (VP) and 41 grafts to group B2 in Tables 4 and 5.
(VP 1 Qa; Fig. 1). Thirty thrombotic events occurred (12 in the VP group
In study A, 19 patients were lost during follow-up (8 in and 18 in the VP 1 Qa group), that is, 0.7 per patient-
group A1, 11 in group A2). Reasons included death or year. Five out of the 12 thrombosis in the group B1 were
abstinence of dialysis therapy (N 5 12), transplantation preceded by a positive test, but thrombosis occurred
(N 5 3), refusal of further graft monitoring (N 5 2), or after 2 to 15 days pending the angiography. In all five
change to peritoneal dialysis (N 5 1) or to another center cases, thrombectomy was done, and a venous stenosis
(N 5 1). In study B, 15 patients were lost to follow-up was found. In group B2, 12 out of 18 thromboses were
(8 in group B1, 7 in group B2). Reasons were death (N 5 predicted by one or more positive tests. In seven cases,
8), transplantation (N 5 4), abstinence of dialysis therapy thrombosis occurred after 3 to 20 days pending the angi-
(N 5 1), and change to peritoneal dialysis (N 5 2). ography (all of these seven grafts showed a venous steno-
sis after thrombectomy), and in five cases, interventionDemographic patient characteristics for both studies
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Table 1. Patient characteristics
Study A Study B
VP (A1) Qa (A2) P VP (B1) VP 1 Qa (B2) P
Patients 24 27 NS 31 37 NS
Median age years (range) 65 (26–86) 66 (21–84) NS 65 (19–80) 61 (21–87) NS
Mean age years (SD) 61 (17) 61 (18) 62 (14) 60 (17)
Gender
Male 9 18 0.04 15 16 NS
Female 15 9 16 21
Cause of renal failure
Diabetes 4 (16%) 7 (26%) NS 8 (26%) 4 (11%) NS
Hypertension 8 8 2 2
Glomerulonephritis 3 2 3 2
Polycystic kidney disease 3 0 0 5
Other 4 7 13 19
Unknown 2 3 5 5
Race
Caucasian 18 (75%) 23 (85%) NS 30 (97%) 30 (81%) NS
Black 5 4 0 4
Asian 1 0 1 3
Median HD therapy months (range) 18.1 (2.3–88.8) 13.9 (0.9–116.7) NS 22.0 (0.0–281.0) 24.8 (0.2–302.1) NS
Mean HD therapy months (SD) 27.9 (26.9) 22.6 (28.2) 43.9 (58.2) 44.3 (69.6)
Abbreviations are: VP, venous pressure; Qa, access flow; HD, hemodialysis; SD, standard deviation.
Table 2. Which positive test led to intervention? that thrombosis rates in patients monitored and selected
for corrective interventions based on VP or Qa can beStudy A Study B
maintained below the quality of care standards formu-VP (A1) Qa (A2) VP (B1) VP 1 Qa (B2)
lated by the NKF-DOQI committee [4]. Second, we show
VP0/MAP 15 — 12 6
that thrombosis rates in groups monitored by VP or QaVP200 0 — 4 0
VP0/MAP 1 VP200a 15 — 9 8 alone or by the combination of tests do not differ. Third,
Qa — 25 — 3 only a small minority of patients was selected for correc-
Qa 1 VPb — — — 13
tive interventions by Qa alone in the group with com-Total (PTA) 30 (26) 25 (22) 25 (23) 30 (26)
bined monitoring of VP and Qa. Fourth, after obtainingAbbreviations are: VP, venous pressure; Qa, access flow; MAP, mean arterial
pressure; PTA, percutaneous transluminal angioplasty. abnormal tests, subsequent diagnostic and interventional
a Both tests were positive procedures should be instituted on short notice. It seemsb VP means either a positive VP0/MAP or a positive VP200, or both
likely that the number of thromboses during the waiting
time can be reduced. Finally, we confirm that static VP is
was not done for various reasons, including graft infec- more effective than dynamic VP for monitoring dialysis
tion, poor clinical condition, and switch to peritoneal grafts.
dialysis. In 13 cases, thrombosis was not preceded by a The present study confirms the usefulness of VP and
positive test, resulting in a thrombosis frequency of 0.32 Qa measurements as access surveillance variables. Pre-
(group B1) and 0.28 (group B2, P 5 NS). Ten of these 13 viously, we have presented the theoretical basis for the
thromboses were treated by radiological thrombolysis. assumption that Qa measurements are better than VP
Stenoses were found at the venous anastomosis (N 5 5, (that is, dynamic) measurements as a monitoring tool
group B1; N 5 3, group B2), at the arterial anastomosis [26]. This is based on the fact that some stenoses are
(N 5 1, group B2), or at both anastomoses (N 5 1, located in the arterial flow tract that is upstream of the
group B2). In three grafts, it was impossible to obtain
venous needle. These lesions increase resistance and re-
anatomical information because no attempt was made
duce Qa without increasing VP, possibly even decreasingto re-establish patency.
VP. Several studies have indicated that arterial stenosesKaplan–Meier survival curves did not show a significant
occur in up to 29% of thrombosis cases [20–23]. In thedifference between the subgroups (Table 5 and Fig. 3).
present study, we found a strong predominance of ve-The six-month event-free survival (an event that equals
nous lesions in the patients referred for angiography.thrombosis not predicted by the test) was 85% for the
In some patients having a graft thrombosis without aVP group and 88% for the VP 1 Qa group (P 5 NS).
preceding positive test, thrombectomy was done. Also,
in those patients, venous lesions were more likely than
DISCUSSION arterial lesions.
Access flow measurements have already been recog-This randomized, prospective, multicenter trial allows
a number of important conclusions. First, we confirm nized as the preferred monitoring tool for vascular access
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Table 3. Localization of stenotic lesions in grafts of patients referred for PTA
Study A Study B
VP (A1) Qa (A2) VP (B1) VP 1 Qa (B2)
Localization
Venous graft 6 outflowa 24 (92%) 19 (86%) 22 (96%) 20 (77%)
Arterial graftb 0 (0%) 1 (5%) 0 (0%) 1 (4%)
Venous 1 arterial graftc 2 (8%) 2 (9%) 1 (4%) 5 (19%)
Total PTA 26 22 23 26
a Stenosis at or near the venous anastomosis and/or in the venous outflow tract
b Stenosis at or near the arterial anastomosis
c Combination of a and b, that is, a stenosis at or near the venous anastomosis and/or in the venous outflow tract, and a stenosis at or near the arterial anastomosis
Table 4. Graft characteristics
Study A Study B
VP (A1) Qa (A2) P VP (B1) VP 1 Qa (B2) P
Grafts 25 28 31 41
Median age of graft months (range) 6.7 (1.0–49.7) 4.6 (1.2–28.4) NS 11.6 (0.0–73.6) 6.0 (0.0–100.0) NS
Mean age graft months (SD) 12.8 (13.8) 8.3 (7.6) 18.1 (20.9) 16.4 (24.8)
Configuration graft
Looped, forearm 23 26 NS 31 37 NS
Straight, upper arm 2 2 0 4
Anticoagulant therapy
Acenocoumerol 14 15 20 23
Aspirin 5 2 3 5
Combination 1 0 2 0
None 5 11 6 13
Follow-up
patient-years 21.3 16.5 21.6 21.1
median months (range) 11.2 (0.9–15.5) 5.8 (1.1–15.2) 0.016 5.9 (1.7–20.4) 5.1 (0.4–20.4) NS
mean months (SD) 10.4 (4.4) 7.2 (4.9) 8.4 (5.7) 6.2 (4.9)
Table 5. Results
Study A Study B
VP (A1) Qa (A2) P VP (B1) VP 1 Qa (B2) P
Interventions/patient-year (N patients) 1.41 (17) 1.52 (11) 1.16 (16) 1.42 (20)
Balloon angioplasty (N) 26 22 23 26
Surgical (N) 4 3 2 4
Thromboses total (N patients) 6 (4) 6 (4) 12 (10) 18 (16)
Predicted/unpredicted 2/4 2/4 5/7 12/6
Unpredicted thromboses/patient-year 0.19 0.24 NS 0.32 0.28 NS
6 month event-freea survival rate % 87 84 NS 85 88 NS
12 month event-freea survival rate % 77 84 NS 85 80 NS
a An event is defined as an unpredicted thrombosis
surveillance [4, 27]. However, these recommendations most effective program [18]. Furthermore, the study pop-
ulation of Sands et al consisted predominantly of AVare primarily based on clinical studies with a nonrandom-
ized or observational setup [19, 25, 28–30]. To our knowl- fistulae (almost two thirds in the control and monitored
groups), which are less likely to clot. Also, the thresholdedge, only one study compared Qa with static VP as
surveillance variable. Sands et al showed that interven- for referral for angiogram (750 vs. 600 mL/min in our
Qa groups) and frequency of measurements (monthlytion based on monthly Qa measurement or on monthly
static VP measurements reduced thrombosis rates in VP vs. weekly in our VP groups) differed. There is some
controversy about the optimal frequency. Some advocatecomparison with nonmonitored controls [8]. Some im-
portant differences between the two studies exist. The the use of dynamic pressures weekly and static VP every
two weeks [4], and others suggest measuring dynamicpresent study also includes a program combining VP and
Qa. Theoretically, this combination is likely to be the VP every dialysis [27] or static VP every week [31]. In
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Fig. 2. Study A: Graft survival with nonpredicted thrombosis. Symbols Fig. 3. Study B: Graft survival with nonpredicted thrombosis. Symbols
are: (m) venous pressure (VP); (h) access flow (Qa). are: (m) venous pressure (VP); (h) VP 1 access flow (Qa).
the present study, we measured both dynamic and static seems likely that immediate institution of further treat-
VP once weekly during the same dialysis session. Our ment could have decreased the number of thromboses.
results indicate that graft surveillance using VP or Qa The 21 thromboses that were not preceded by positive
measurements strictly organized as in the present study tests should not all be considered as failures of the tests.
results in identical thrombosis rates. This does not ex- Flow is directly related to blood pressure. Blood pressure
clude the possibility that in patients who develop more may show considerable variability in hemodialysis pa-
arterial lesions for whatever reason, surveillance using tients and is likely to reach its lowest levels in the first
Qa would result in lower thrombosis rates than using hours after the hemodialysis session and especially dur-
VP measurements. ing the night [34]. Therefore, it is possible that flow is
In our study, most referrals for intervention in patients adequate at the time measurements are done, but
monitored by VP measurements alone (groups A1 and reaches levels associated with thrombosis in the interdia-
B1) were based on static VP measurements. Although lytic period.
dynamic VP was successfully used as part of an access Several issues need to be addressed with respect to
surveillance program in some studies [6, 11, 16, 32], there the present study.
is convincing evidence that dynamic VP does not accu- First, our power calculations were based on the as-
rately reflect true intra-access pressure and, therefore, sumption that there would be a difference in thrombosis
rates between VP and Qa monitored patients. However,does not reflect resistance caused by stenosis formation
[14]. Dynamic VP is highly biased by pump flow, blood the strict adherence to the surveillance protocols im-
proved our results using VP measurements when com-tubing, needle size, and blood pressure [33]. Static VP
measurements, on the other hand, particularly when cor- pared with our historic controls. Differences in the pres-
ent study were not statistically significant. The resultsrected for MAP, avoid these potential confounders.
Also in group B2 (a combination of VP and Qa mea- indicated that continuation of the study was not likely
to result in clinically relevant differences.surements), most referrals were based on VP, and only 3
out of 30 referrals were based on Qa alone. These data Second, we measured Qa every two months, but re-
peated the measurement after one month if Qa reachedindicate that when VP measurements are well organized,
adding periodic Qa measurements is of limited value levels between 600 and 800 mL/min. This frequency was
mainly based on feasibility considerations. It remains(groups B1 vs. B2). On the other hand, study A clearly
shows that when no VP measurements are done, periodic unclear whether a higher frequency of Qa measure-
ments, as was suggested by others [8, 27], would decreaseQa measurements result in identical thrombosis rates,
proving the effectiveness of Qa as surveillance variable. the already low thrombosis rate further. Furthermore,
we cannot exclude the possibility that decreasing theIn this study, 21 of the 42 thromboses occurred despite
preceding positive tests. Sixteen thromboses occurred 2 frequency of VP measurements, for instance, every two
weeks, as was suggested elsewhere [4], would result into 20 days after obtaining the abnormal tests pending
further diagnostic and correctional interventions. These identical results.
Additionally, threshold levels for selection for referralresults further support the idea that an increased VP
and/or low Qa indeed predict imminent thrombosis. It may vary. We used a level of 600 mL/min as Qa threshold
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level for referral. We based our choice on earlier results ments are more time consuming, and a special device is
[35] and the NKF-DOQI considerations [4]. Others have needed. We showed that by measuring Qa every four to
chosen 650 or 750 mL/min [8, 27]. This may affect out- eight weeks, identical results can be obtained as with
come. A recent meta-analysis by Paulson et al concluded weekly VP assessments. The decision of which method
that a single Qa measurement did not appear to have to use will be primarily based on the preferences of those
enough accuracy to be a clinically useful predictor of graft involved in the access care and on the possibilities to
thrombosis or failure [36]. Furthermore, it has been sug- implement a certain surveillance strategy.
gested that a decrease in Qa over time of .15% is partic- In conclusion, our studies show that standardized mon-
ularly predictive of impending graft failure [29]. The pres- itoring of VP or Qa or the combination of both and
ent study was not specifically designed to examine that subsequent corrective intervention can decrease throm-
issue. However, in the patients who were monitored by bosis rates to below 0.5 per patient-year, which is recom-
Qa measurements (groups A2 and B2), none of the un- mended by the Vascular Access Task Force of the
predicted thromboses were preceded by a decrease in Qa NKF-DOQI Committee as a quality of care standard
of more than 15%. As a consequence, none of these [4]. When applying the present protocol, VP, Qa, or the
thromboses would have been predicted by this criterion. combination as variables for selection of patients for
Furthermore, in the patients who did not reach the thresh- corrective intervention is equally effective in reducing
old levels of the present study but did show a decrease thrombosis rates in hemodialysis access grafts.
in Qa of more than 15% [N 5 11 (A2), N 5 8 (B2);
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